Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 233

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 233
---
 J. Pomerantz 
     150,000  
     —  
     66,000  
     —  
     216,000 
  
    Hila Karah 
     65,500  
     —  
     27,500  
     —  
     93,000 
  
    Anthony J. Maddaluna 
     69,000  
     —  
     27,500  
     —  
     96,500 
  
    William B. Hayes 
     71,000  
     —  
     27,500  
     —  
     98,500 
  
    Robert E. Martell 
     61,500  
     —  
     27,500  
     —  
     89,000 
  
    Mark Gilbert 
     54,000  
     —  
     27,500  
     —  
     81,500 

(1)
The amounts reported do not reflect the amounts actually received by our non-employee directors. Instead, in accordance with SEC rules,
these amounts reflect the grant date fair value of stock options granted to our non-employee directors during the fiscal year ended December
31, 2024, as computed in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based
compensation transaction. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based
vesting conditions. Assumptions used in the calculation of these amounts are included in Note 5 to our consolidated financial statements
included in our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 13, 2025. Our
non-employee directors who have received options will only realize compensation with regard to these options to the extent the trading
price of our common stock is greater than the exercise price of such options. As of December 31, 2024, our non-employee directors held
the following numbers of stock options: Dr. Pomerantz, 182,000 stock options; Ms. Karah 53,781 stock options, Mr. Maddaluna 53,500 stock
options, Mr. Hayes 53,500 stock options, Mr. Martell 32,500 stock options,